# Otsuka Pharmaceutical Development & Commercialization, Inc.: Phase 3 study started recruiting, 1120 planned (Generalized Anxiety Disorder)

**Score:** 80/100

| Field | Value |
|---|---|
| Sponsor | Otsuka Pharmaceutical Development & Commercialization, Inc. |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Trial of the Safety and Tolerability of SEP-363856 in Adults With Generalized Anxiety Disorder |
| NCT ID | NCT07786454 |
| Phase | Phase 3 |
| Status | recruiting |
| Conditions | Generalized Anxiety Disorder |
| Intervention types | drug |
| Target enrollment | 1120 |
| Site countries | United States |
| Posted | 2026-08-26 |
| Planned start | 2026-10-08 |
| Event | Started recruiting |
| Event date | 2026-10-08 |
| Last update posted | 2026-10-20 |

## Why this score
- Industry sponsor (buys outsourced services).
- Just started recruiting: sites, recruitment and supply are active.
- Phase 3: multi-site, larger budget.
- 1120 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07786454). Last refreshed: 2026-11-03T05:11:05.587Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.